Establishment Labs Announces 3-Year Mia Femtech Clinical Results At 9th World Symposium On Ergonomic Implants; There Were Also No Reports Of Infection, Hematoma, Or Seroma Requiring Intervention In The Study And No Reports Of Changes In Nipple Or Breast Sensation; The Follow-Up Compliance Rate At 3-Years Was 93%

Benzinga · 10/31/2024 12:24

Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain.

The Mia Femtech Clinical Study is an IRB-approved prospective study that enrolled 100 subjects between December 2020 and April 2021. In the preliminary three-year analysis of key complications, there were no reports of capsular contracture (Baker Grade III/IV) and no ruptures (suspected or confirmed). There were also no reports of infection, hematoma, or seroma requiring intervention in the study and no reports of changes in nipple or breast sensation. The follow-up compliance rate at three years was 93%.

Recently
Symbol
Price
%Change